Phaseline

Targets › IGFBP2

IGFBP2 (Insulin-like growth factor-binding protein 2): drug programs, companies and trials

3 programs from 2 companies in 3 trials: 3 Phase 2; Oncology; next expected readout Dec 2026.

Multifunctional protein that plays a critical role in regulating the availability of IGFs such as IGF1 and IGF2 to their receptors and thereby regulates IGF-mediated cellular processes including proliferation, differentiation, and apoptosis in a cell-type specific manner. Functions coordinately with receptor protein tyrosine phosphatase beta/PTPRB and the IGF1 receptor to regulate IGF1-mediated signaling by…. (UniProt, P18065)

Open in Phaseline: the race on IGFBP2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of WashingtonpUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine (WOKVAC)
Plasmid DNA vaccine encoding tumor-associated antigens (IGFBP2, HER2, IGF1R) to stimulate
IGFBP2, HER2, IGF1RPhase 2Anatomic Stage I Breast Cancer AJCC v8Dec 2026
University of WashingtonpUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine
Plasmid DNA vaccine targeting IGFBP-2 protein to stimulate immune response against ovarian
IGFBP2Phase 2Fallopian Tube CarcinomaSep 2027
H. Lee Moffitt Cancer Center and Research InstituteWOKVAC
pUMVC3-based vaccine targeting IGFBP2, HER2, and IGF1R
IGFBP2, ERBB2, IGF1RPhase 2Breast Cancer FemaleDec 2027

Conditions

Fallopian Tube Carcinoma (1) Anatomic Stage I Breast Cancer AJCC v8 (1) Breast Cancer Female (1)

Modalities

mixed (2), other (1)

Companies

University of Washington (2) H. Lee Moffitt Cancer Center and Research Institute (1)

Related targets

IGF1R (2) HER2 (1) ERBB2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.